Accéder au contenu
MilliporeSigma

Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Molecular endocrinology (Baltimore, Md.) (2014-12-17)
Yan-Dong Wang, Wei-Dong Chen, Cunbao Li, Cong Guo, Yanyan Li, Hui Qi, Hailing Shen, Jing Kong, Xuecheng Long, Frank Yuan, Xichun Wang, Wendong Huang
RÉSUMÉ

The farnesoid X receptor (FXR) is a key metabolic and homeostatic regulator in the liver. In the present work, we identify a novel role of FXR in antagonizing c-Jun N-terminal kinase (JNK) signaling pathway in liver carcinogenesis by activating superoxide dismutase 3 (SOD3) transcription. Compared with wild-type mouse liver, FXR(-/-) mouse liver showed elevated JNK phosphorylation. JNK1 deletion suppressed the increase of diethylnitrosamine-induced tumor number in FXR(-/-) mice. These results suggest that JNK1 plays a key role in chemical-induced liver carcinogenesis in FXR(-/-) mice. We found that ligand-activated FXR was able to alleviate H₂O₂or tetradecanoylphorbol acetate-induced JNK phosphorylation in human hepatoblastoma (HepG2) cells or mouse primary hepatocytes. FXR ligand decreased H₂O₂-induced reactive oxygen species (ROS) levels in wild-type but not FXR(-/-) mouse hepatocytes. FXR knockdown abolished the inhibition of 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]-Benzoic acid (GW4064) on JNK phosphorylation and ROS production induced by H₂O₂in HepG2 cells. The gene expression of SOD3, an antioxidant defense enzyme, was increased by FXR activation in vitro and in vivo. An FXR-responsive element, inverted repeat separated by 1 nucleotide in SOD3 promoter, was identified by a combination of transcriptional reporter assays, EMSAs, and chromatin immunoprecipitation assays, which indicated that SOD3 could be a direct FXR target gene. SOD3 knockdown abolished the inhibition of GW4064 on JNK phosphorylation induced by H₂O₂in HepG2 cells. In summary, FXR may regulate SOD3 expression to suppress ROS production, resulting in decreasing JNK activity. These results suggest that FXR, as a novel JNK suppressor, may be an attractive therapeutic target for liver cancer treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide benzoique, ACS reagent, ≥99.5%
Supelco
Acide benzoique, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Chenodeoxycholic acid
Supelco
Melting point standard 121-123°C, analytical standard
Supelco
Acide benzoique, analytical standard, (for the calibration of the melting point system), traceable to primary standards (LGC)
Sigma-Aldrich
N-Nitrosodiethylamine, liquid
Sigma-Aldrich
N-Nitrosodiethylamine, ISOPAC®
Sigma-Aldrich
Acide benzoique, meets analytical specification of Ph. Eur., BP, USP, FCC, E210, 99.5-100.5% (alkalimetric)
Sigma-Aldrich
Acide benzoique, ≥99.5%, FCC, FG
USP
Acide benzoique, United States Pharmacopeia (USP) Reference Standard
Supelco
Acide benzoique, reference material for titrimetry, certified by BAM, ≥99.5%
Sigma-Aldrich
N-Nitrosodiethylamine, ≥99.0% (GC)
Supelco
N-Nitrosodiethylamine, analytical standard
Sigma-Aldrich
Acide benzoique, ReagentPlus®, 99%
Sigma-Aldrich
Acide benzoique, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9% (alkalimetric)
Sigma-Aldrich
Acide benzoique, natural, ≥99.5%, FCC, FG
Supelco
Acide benzoique, Standard for quantitative NMR, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland